Home / Health / FDA Greenlights Revolution Meds Cancer Drug
FDA Greenlights Revolution Meds Cancer Drug
25 Jul
Summary
- FDA accepted Revolution Medicines' New Drug Application for daraxonrasib.
- Daraxonrasib is being developed for pancreatic cancer.
- Regulatory review is now underway in both the US and Europe.
Revolution Medicines has achieved a key milestone with the FDA's acceptance of its New Drug Application (NDA) for daraxonrasib. This targeted oncology treatment is being developed as a novel inhibitor for pancreatic cancer, addressing a significant unmet medical need.
Daraxonrasib's selection for the FDA Commissioner's National Priority Voucher program highlights its potential impact. Formal U.S. regulatory review is now underway. Concurrently, European authorities have initiated their assessment of daraxonrasib.
This dual review process in both the United States and Europe signifies a critical phase for Revolution Medicines. The company, focused on innovative cancer therapies, is advancing daraxonrasib as a potential first-in-class treatment for pancreatic ductal adenocarcinoma.
